Thomson CenterWatch recently launched a content management service to assist sponsors in complying with the latest requirements for clinical trial transparency. This web based program serves as a tool for sponsors to register their active clinical trials and publish their clinical trial results while following the data field guidelines established by clinicaltrials.gov and the World Health Organization and ICMJE.
Thomson CenterWatch recently launched a content management service to assist sponsors in complying with the latest requirements for clinical trial transparency. This web based program serves as a tool for sponsors to register their active clinical trials and publish their clinical trial results while following the data field guidelines established by clinicaltrials.gov and ICMJEthe World Health Organization and ICMJE.
Using the latest and most secure web-enabled technology, sponsors can efficiently create, manage and publish their clinical trial information from anywhere. Thomson CenterWatch serves as the central repository for the trial content and then distributes registry and results information to mandated web sites in accordance with the latest guidelines.
For over a decade, Thomson CenterWatch has been informing patients and health professionals about ongoing clinical trials. Their Clinical Trials Listing Service™ currently contains nearly 20,000 active listings and is integrated within the web sites of over 80 health associations and patient advocacy groups.
Other benefits of Thomson CenterWatch's Registry/Results Service:
› Accessibility: WebMD, the Discovery Health Channel, Washington Post, Newsweek,PDR.net and thousands of other web sites and feature Thomson CenterWatch clinical trials content
› Compliance:Thomson CenterWatch keeps current with disclosure issues and updates
› Visibility: Consistently ranks #1 or 2 on all major search engines for clinical trials information, including Google and Yahoo
› Exposure: In 2004, www.centerwatch.com received over 10 million visitors
› Credibility: A business of Thomson Scientific and Healthcare, a division of the Thomson Corporation (NYSE:TOC)
For more information on how Thomson CenterWatch can help you with your clinical trial related needs visit http://www.centerwatch.com or contact David Heck at (513) 754-1705 or [email protected]
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
January 20th 2025Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS G12C-mutated metastatic colorectal cancer.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.